These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 38010260)

  • 1. Longitudinal Circulating Tumor DNA Modeling to Predict Disease Progression in First-Line Mutant Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer.
    Johnson M; Serra Traynor C; Vishwanathan K; Overend P; Hartmaier R; Markovets A; Chmielecki J; Mugundu GM; Barrett JC; Tomkinson H; Ramalingam SS
    Clin Pharmacol Ther; 2024 Feb; 115(2):349-360. PubMed ID: 38010260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer.
    Gray JE; Okamoto I; Sriuranpong V; Vansteenkiste J; Imamura F; Lee JS; Pang YK; Cobo M; Kasahara K; Cheng Y; Nogami N; Cho EK; Su WC; Zhang G; Huang X; Li-Sucholeiki X; Lentrichia B; Dearden S; Jenkins S; Saggese M; Rukazenkov Y; Ramalingam SS
    Clin Cancer Res; 2019 Nov; 25(22):6644-6652. PubMed ID: 31439584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The presence and variant allele fraction of EGFR mutations in ctDNA and development of resistance.
    O'Kane GM; Liu G; Stockley TL; Shabir M; Zhang T; Law JH; Le LW; Sacher A; Shepherd FA; Bradbury PA; Leighl NB
    Lung Cancer; 2019 May; 131():86-89. PubMed ID: 31027703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small-cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial.
    Remon J; Besse B; Aix SP; Callejo A; Al-Rabi K; Bernabe R; Greillier L; Majem M; Reguart N; Monnet I; Cousin S; Garrido P; Robinet G; Garcia Campelo R; Madroszyk A; Mazières J; Curcio H; Wasąg B; Pretzenbacher Y; Fournier B; Dingemans AC; Dziadziuszko R
    Ann Oncol; 2023 May; 34(5):468-476. PubMed ID: 36863484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study.
    Cheng Y; He Y; Li W; Zhang HL; Zhou Q; Wang B; Liu C; Walding A; Saggese M; Huang X; Fan M; Wang J; Ramalingam SS
    Target Oncol; 2021 Mar; 16(2):165-176. PubMed ID: 33544337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase II Trial of Osimertinib in the Second-Line Treatment of Non-small Cell Lung Cancer with the EGFR T790M Mutation, Detected from Circulating Tumor DNA: LiquidLung-O-Cohort 2.
    Park CK; Cho HJ; Choi YD; Oh IJ; Kim YC
    Cancer Res Treat; 2019 Apr; 51(2):777-787. PubMed ID: 30189719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase II Trial of Osimertinib as the First-Line Treatment of Non-Small Cell Lung Cancer Harboring Activating EGFR Mutations in Circulating Tumor DNA: LiquidLung-O-Cohort 1.
    Park CK; Cho HJ; Choi YD; Oh IJ; Kim YC
    Cancer Res Treat; 2021 Jan; 53(1):93-103. PubMed ID: 32972042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of circulating tumour DNA to identify patients with epidermal growth factor receptor-positive non-small cell lung cancer who might benefit from sequential tyrosine kinase inhibitor treatment.
    Provencio M; Serna-Blasco R; Franco F; Calvo V; Royuela A; Auglytė M; Sánchez-Hernández A; de Julián Campayo M; García-Girón C; Dómine M; Blasco A; Sánchez JM; Oramas J; Bosch-Barrera J; Sala MÁ; Sereno M; Ortega AL; Chara L; Hernández B; Padilla A; Coves J; Blanco R; Balsalobre J; Mielgo X; Bueno C; Jantus-Lewintre E; Molina-Vila MÁ; Romero A
    Eur J Cancer; 2021 May; 149():61-72. PubMed ID: 33831609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clearing of circulating tumour DNA predicts clinical response to osimertinib in EGFR mutated lung cancer patients.
    Boysen Fynboe Ebert E; McCulloch T; Holmskov Hansen K; Linnet H; Sorensen B; Meldgaard P
    Lung Cancer; 2020 May; 143():67-72. PubMed ID: 32213382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longitudinal nonlinear mixed effects modeling of EGFR mutations in ctDNA as predictor of disease progression in treatment of EGFR-mutant non-small cell lung cancer.
    Janssen JM; Verheijen RB; van Duijl TT; Lin L; van den Heuvel MM; Beijnen JH; Steeghs N; van den Broek D; Huitema ADR; Dorlo TPC
    Clin Transl Sci; 2022 Aug; 15(8):1916-1925. PubMed ID: 35775126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer.
    Ramalingam SS; Yang JC; Lee CK; Kurata T; Kim DW; John T; Nogami N; Ohe Y; Mann H; Rukazenkov Y; Ghiorghiu S; Stetson D; Markovets A; Barrett JC; Thress KS; Jänne PA
    J Clin Oncol; 2018 Mar; 36(9):841-849. PubMed ID: 28841389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Study Design and Rationale for the PACE-LUNG Trial: A Multicenter, Single-Arm, Phase II Clinical Trial Evaluating the Efficacy of Additional Chemotherapy for Patients with EGFRm NSCLC with the Continued Presence of Plasma ctDNA EGFRm at Week 3 After Start of Osimertinib First-Line Treatment.
    Acker F; Aguinarte L; Althoff F; Heinzen S; Rost M; Wild P; Reiser L; Mänz M; Meyer F; Stratmann J; Sebastian M
    Clin Lung Cancer; 2022 Nov; 23(7):e473-e477. PubMed ID: 36089483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
    Soria JC; Ohe Y; Vansteenkiste J; Reungwetwattana T; Chewaskulyong B; Lee KH; Dechaphunkul A; Imamura F; Nogami N; Kurata T; Okamoto I; Zhou C; Cho BC; Cheng Y; Cho EK; Voon PJ; Planchard D; Su WC; Gray JE; Lee SM; Hodge R; Marotti M; Rukazenkov Y; Ramalingam SS;
    N Engl J Med; 2018 Jan; 378(2):113-125. PubMed ID: 29151359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II Study Evaluating the Mechanisms of Resistance on Tumor Tissue and Liquid Biopsy in Patients With EGFR-mutated Non-pretreated Advanced Lung Cancer Receiving Osimertinib Until and Beyond Radiologic Progression: The MELROSE Trial.
    Bennouna J; Girard N; Audigier-Valette C; le Thuaut A; Gervais R; Masson P; Marcq M; Molinier O; Cortot A; Debieuvre D; Cadranel J; Lena H; Moro-Sibilot D; Chouaid C; Mennecier B; Urban T; Sagan C; Perrier L; Barlesi F; Denis MG
    Clin Lung Cancer; 2020 Jan; 21(1):e10-e14. PubMed ID: 31648999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osimertinib benefit in EGFR-mutant NSCLC patients with T790M-mutation detected by circulating tumour DNA.
    Remon J; Caramella C; Jovelet C; Lacroix L; Lawson A; Smalley S; Howarth K; Gale D; Green E; Plagnol V; Rosenfeld N; Planchard D; Bluthgen MV; Gazzah A; Pannet C; Nicotra C; Auclin E; Soria JC; Besse B
    Ann Oncol; 2017 Apr; 28(4):784-790. PubMed ID: 28104619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overall Survival with Osimertinib in Untreated,
    Ramalingam SS; Vansteenkiste J; Planchard D; Cho BC; Gray JE; Ohe Y; Zhou C; Reungwetwattana T; Cheng Y; Chewaskulyong B; Shah R; Cobo M; Lee KH; Cheema P; Tiseo M; John T; Lin MC; Imamura F; Kurata T; Todd A; Hodge R; Saggese M; Rukazenkov Y; Soria JC;
    N Engl J Med; 2020 Jan; 382(1):41-50. PubMed ID: 31751012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating Tumor DNA T790M Testing as a Predictor of Osimertinib Efficacy in Epidermal Growth Factor Receptor Mutant Non-small Cell Lung Cancer: A Single Center Experience.
    Makarov M; Peled N; Shochat T; Zer A; Rotem O; Dudnik E
    Isr Med Assoc J; 2019 Jun; 21(6):394-398. PubMed ID: 31280508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma ctDNA monitoring during epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor treatment in patients with EGFR-mutant non-small cell lung cancer (JP-CLEAR trial).
    Usui K; Yokoyama T; Naka G; Ishida H; Kishi K; Uemura K; Ohashi Y; Kunitoh H
    Jpn J Clin Oncol; 2019 Jun; 49(6):554-558. PubMed ID: 30809659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FDA Benefit-Risk Assessment of Osimertinib for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation.
    Odogwu L; Mathieu L; Goldberg KB; Blumenthal GM; Larkins E; Fiero MH; Rodriguez L; Bijwaard K; Lee EY; Philip R; Fan I; Donoghue M; Keegan P; McKee A; Pazdur R
    Oncologist; 2018 Mar; 23(3):353-359. PubMed ID: 29242281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating tumor DNA analysis of EGFR-mutant non-small cell lung cancer patients receiving osimertinib following previous tyrosine kinase inhibitor treatment.
    Beagan JJ; Bach S; van Boerdonk RA; van Dijk E; Thunnissen E; van den Broek D; Weiss J; Kazemier G; Pegtel DM; Bahce I; Ylstra B; Heideman DAM
    Lung Cancer; 2020 Jul; 145():173-180. PubMed ID: 32460198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.